Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics.
about
Developmental pharmacokinetics in pediatric populationsSingle-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents.A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease.Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patientsNon-Specific Gastric Inflammation in Children is Associated with Proton Pump Inhibitor Treatment for More than 6 Weeks.Clinical utility of esomeprazole for treatment of gastroesophageal reflux disease in pediatric and adolescent patients.Gastroesophageal reflux disease in children and adolescents: when and how to treat.Diagnosis and management of gastroesophageal reflux disease (GERD): an Indian perspective.Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics.Comparative safety and efficacy of proton pump inhibitors in paediatric gastroesophageal reflux disease.The stereoselectivity of CYP2C19 on R- and S-isomers of proton pump inhibitors.Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years.Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment.Toxicology and toxicokinetics of oral pantoprazole in neonatal and juvenile dogs.Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures.Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years.Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.
P2860
Q27002933-D698C66F-009F-411F-8AFD-8A2FC3D09313Q33355914-B626A283-08B7-4FF7-B1FF-11351720F8ECQ35308159-3AC802CD-2F91-4562-8003-6A745036E1DCQ37161518-233FAEB0-1F4A-41A3-AFB8-C4FA161A7F82Q37494172-9C79AA19-B6C0-4241-BF2F-DB9EB1402A7EQ37561598-02136D69-745D-4F79-BB29-0800A9B55E7BQ37960158-F309D0DA-B6CC-437F-9D04-0EA92A76E2FEQ38080437-C596C988-C444-4756-9DDA-A1C66B62F9F8Q38091317-BC9D8D82-0A6B-487F-AF8F-D9061D68983AQ38202595-30F07EC5-4680-48A7-9921-982D4E0FFC9AQ39292057-7C3F4D49-452E-402F-BA3D-11973B4ACCB6Q40471212-2260F3B7-0839-4DDD-9B0D-5DF301E16738Q46322531-21397BF1-F952-46A0-99F2-D611856A2F64Q48170836-9D921B6A-3078-4537-9D53-F8070B997286Q48961662-B2B06440-A058-41FA-975F-C4C1740F81C2Q49493799-582A4E46-66D7-4064-880B-84BF690C8AEEQ50450387-30D674F7-DC57-42D5-891E-050D1DA47FA0Q55280841-57FF386C-E0AE-4EF4-B165-538F11742511
P2860
Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics.
@ast
Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics.
@en
type
label
Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics.
@ast
Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics.
@en
prefLabel
Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics.
@ast
Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics.
@en
P1476
Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics.
@en
P2093
Gregory L Kearns
Harland S Winter
P356
10.1097/00005176-200311001-00011
P407
P478
37 Suppl 1
P577
2003-11-01T00:00:00Z